NuProbe, a Cambridge, MA-based early stage molecular diagnostics company, raised $11m in Series A funding.
The round was co-led by Sequoia China and Serica Partners, with participation from WuXi AppTec Corporate Ventures.
The company intends to use the funds to grow staff in its Cambridge, Mass. and China offices, and to continue technology development, clinical trials and commercialization.
Developed at and licensed from Harvard University’s Wyss Institute for Biologically Inspired Engineering and Rice University, NuProbe is advancing an ultra-sensitive, non-invasive blood test for the early detection of cancer and infectious diseases.
In pre-clinical trials, the company’s technology improved qPCR and NGS mutation detection sensitivity by 10-100 fold with limit of detection down to 0.01 percent, and showed a multiplexing capability of 10-100 reactions for detecting hundreds of mutations in the same test tube.
NuProbe was co-founded by David Yu Zhang, Ph.D., and Victor Shi, Ph.D., CEO.